A Bioelectronic Sensor for Rapid Assessment of Antibody Titer and Glycan Structure
This project will result in a scalable, microfluidic system for rapid and informative analytical measurements that will bolster the development of vaccines and therapeutics for coronavirus.
Categories
Proteins/ Antibodies
Vaccines
Process control
Industry Need
The biomanufacturing industry would benefit from rapid, scalable, and informative analytical measurements for use during biologics production that would speed up the development and production of vaccines and therapeutics.
Solution
The University of Maryland, College Park, aimed to develop a microfluidic analytic devicefor the rapid quantification of antibody titer and N-linked galactosylation. The device is integrated with bioelectronic sensor technology that can quickly inform the total proportion of galactosylated antibodies in a sample. If successful, this device would reduce cost and time associated with the development and production processes of biologics by generating rapid analysis of vital analytical features of antibody therapeutics.
Impacts
The University of Maryland developed a novel platform for rapid analysis of vital analytical features of antibody therapeutics such as antibody titer and glycan structure. This integrated device and sensor technology will help improve the process development and production efficiency of critically important vaccines and therapeutics for the coronavirus response effort.
Publications
Motabar, D., Wang, S., Tsao, C., Payne, G. F., & Bentley, W. E. (2022). Protein G: beta-galactosidase fusion protein for multi-modal bioanalytical applications. Biotechnology Progress, 38(6), e3297. https://doi.org/10.1002/btpr.3297
Additional Project Information (Members Only)
Login to the NIIMBL member portal to access more, including: